MAY 05, 2020 9:00 AM PDT

The Pharmacogenomics Behind the Investigational Treatments of COVID-19 and its High-Risk Underlying Conditions

Sponsored by: Admera Health
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Senior Clinical Pharmacogenomics Specialist, Medical Affairs Department, Admera Health
    Biography
      Becky Winslow is an accomplished Doctor of Clinical Pharmacy with more than twenty years of clinical pharmacotherapy and pharmacy business operations experience, which includes seven years of direct patient-facing care, seven years of pharmacy management experience, and six years of experience as a medical science liaison in the pharmacogenomics field. Becky excels at developing and managing collaborative relationships with healthcare professionals and key opinion leaders to stay abreast of emerging trends and to achieve project goals. Becky is an articulate communicator with an extensive background in gathering and critically analyzing research and data, translating complex content into a level appropriate for the target audience, writing clinical and marketing material, presenting, teaching, and training. Becky has consulted on several notable pharmacogenomics endeavors, including training the consultant pharmacists in the "Know Your Rx Coalition," consulting for Cedarville University's Pharmacogenomics Excellence Program, and leading the project to integrate pharmacogenomics into Apollo Vanguard's suite of employee benefits. Becky Winslow is a registered provider for the Test2Learn(TM) Community Pharmacogenomics Certificate Program and a member of both the Clinical Pharmacogenetics Implementation Consortium and the Get the Medications Right Institute. She is currently both the Senior Clinical Pharmacogenomics Specialist and the Fellowship Program Didactic Director in the Medical Affairs Department at Admera Health.

    Abstract
    DATE:  May 5, 2020
    TIME:   9:00am PT, 12:00pm ET
     
    As of May 4, 2020, 1,152,372 total COVID-19 cases and 67,456 total deaths have been reported in the United States (U.S.). Fifty-five U.S. jurisdictions have reported cases including the 50 states, the District of Columbia, Puerto Rico, Guam, the Northern Mariana Islands, and the U.S. Virgin Islands. According to the CDC, older adults and people of any age who have severe underlying medical conditions such as diabetes, chronic lung disease, cardiovascular disease, and any disease that causes the patient to be immunocompromised might be at higher risk for contracting and experiencing severe illness from COVID-19. Most patients with significant underlying chronic medical conditions take medications to mitigate their disease. Also, some patients take medicines that can induce immunosuppression and increase their chances of contracting COVID-19. Pharmacogenomics directed medication therapy management before infection with COVID-19 has the potential to reduce the chances of patients with chronic disease contracting COVID-19 and, it increases their chances for survival from COVID-19 should they become infected. COVID-19 is a novel coronavirus that, once contracted, manifests itself through a wide range of symptoms. The symptoms range anywhere between no signs of COVID-19 at all to death from COVID-19 induced pathophysiology. Many medications are currently proposed for treating COVID-19, and many drugs are now being used to treat COVID-19's sequelae, such as acute respiratory distress syndrome, sepsis, and coagulopathy. Pharmacogenomics directed medication management also has the potential to improve the efficacy of and decrease the toxicity of some medications used to treat COVID-19 and its most common sequelae.
     
    Learning Objectives:
    • Describe how pharmacogenomics directed medication therapy management before infection with COVID-19 has the potential to reduce the chances for patients with chronic disease contracting COVID-19
    • Describe how pharmacogenomics directed medication management has the potential to improve the efficacy of and decrease the toxicity of some medications used to treat COVID-19 and its sequelae
     
     
    Webinars will be available for unlimited on-demand viewing after live event.
     
    LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

     

     


    Show Resources
    You May Also Like
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    JUN 23, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 23, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
    MAR 03, 2020 9:00 AM JST
    C.E. CREDITS
    MAR 03, 2020 9:00 AM JST
    DATE: March 3, 2020 TIME: 9:00am JST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the e...
    FEB 25, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 25, 2020 9:00 AM PST
    Learn about how to generate a small scale CAR-T workflow using ThermoFisher products See detailed characterization tools that can be utilized and applied in a CAR-T workflow...
    Loading Comments...
    Show Resources
    Attendees
    • See more